{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:11:17Z","timestamp":1789708277727,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clinthera.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T10:23:55Z","timestamp":1537784635000},"page":"1347-1356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers"],"prefix":"10.1016","volume":"40","author":[{"given":"Cheng-zi","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-7293","authenticated-orcid":false,"given":"Wen-xing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-fang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.06.009_bib0001","first-page":"927","article-title":"Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect","volume":"25","author":"Chen","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bcpt.12117","article-title":"Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives","volume":"114","author":"Bruno","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0003","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/ecp.11.36","article-title":"Managing the adverse effects of nonsteroidal anti-inflammatory drugs","volume":"4","author":"Patrignani","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0004","first-page":"A7311","article-title":"[Cardiovascular and gastrointestinal safety of NSAIDs]","volume":"158","author":"van den Bemt","year":"2014","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0005","first-page":"255","article-title":"Gastrointestinal damage by non-steroidal anti-inflammatory drugs: updated clinical considerations","volume":"60","author":"Pellicano","year":"2014","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0006","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3748\/wjg.v18.i18.2147","article-title":"Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility","volume":"18","author":"Takeuchi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0007","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40261-013-0052-6","article-title":"Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice","volume":"33","author":"Patricio","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0008","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1570163811666140127123717","article-title":"Selective cyclooxygenase inhibitors: current status","volume":"11","author":"Nandakishore","year":"2014","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0009","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1871523011312010008","article-title":"Cardiovascular adverse effects of anti-inflammatory drugs","volume":"12","author":"Roubille","year":"2013","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1024\/1661-8157\/a001074","article-title":"[Cardiovascular risk of non-steroidal anti-inflammatory drugs]","volume":"101","author":"Hermann","year":"2012","journal-title":"Praxis (Bern 1994)"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0011","first-page":"542","article-title":"[Cardiovascular safety of non-steroidal anti-inflammatory drugs]","volume":"135","author":"Mollersen","year":"2015","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2018.06.009_bib0012","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar4175","article-title":"Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage","volume":"15","author":"Sostres","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0013","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tcm.2016.04.011","article-title":"FDA labeling of NSAIDs: review of nonsteroidal anti-inflammatory drugs in cardiovascular disease","volume":"26","author":"Pirlamarla","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0014","first-page":"767","article-title":"Selective inhibition of cyclooxygenase-2: risks and benefits","volume":"52","author":"Mendes","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/med.21331","article-title":"Recent developments in chimeric NSAIDs as safer anti-inflammatory agents","volume":"35","author":"Suthar","year":"2015","journal-title":"Med Res Rev"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0016","first-page":"762","article-title":"Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages","volume":"23","author":"Shen","year":"2002","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0017","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1745-7254.2006.00312.x","article-title":"Formation of 4\u2032-carboxyl acid metabolite of imrecoxib by rat liver microsomes","volume":"27","author":"Xu","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0018","first-page":"912","article-title":"[Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs]","volume":"40","author":"Li","year":"2005","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0019","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.bmcl.2009.02.090","article-title":"Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib","volume":"19","author":"Feng","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1745-7254.2006.00265.x","article-title":"Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib","volume":"27","author":"Xu","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0021","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0009-9236(03)00120-6","article-title":"Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans","volume":"74","author":"Werner","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0022","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/00498250600595524","article-title":"Metabolism and excretion of imrecoxib in rat","volume":"36","author":"Xu","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0023","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0024","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/tpj.2013.2","article-title":"CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database","volume":"14","author":"Dai","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00003088-200342030-00003","article-title":"Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib","volume":"42","author":"Brenner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0026","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","article-title":"Drug-drug interaction studies: regulatory guidance and an industry perspective","volume":"15","author":"Prueksaritanont","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0028","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1208\/s12248-013-9530-2","article-title":"Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach","volume":"15","author":"Tod","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.06.009_bib0030","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.12659\/MSM.901727","article-title":"The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels","volume":"23","author":"Gao","year":"2017","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.clinthera.2018.06.009_bib0031","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"10.1016\/j.clinthera.2018.06.009_bib0032","article-title":"Phase I Clinical Tolerability of Imrecoxib","volume":"46","author":"Huang","year":"2011","journal-title":"Chin Pharm J"},{"issue":"3","key":"10.1016\/j.clinthera.2018.06.009_bib0033","article-title":"Discovery of imrecoxib","volume":"21","author":"Guo","year":"2012","journal-title":"Chinese Journal of New Drugs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T10:52:03Z","timestamp":1537786323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818302601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0149291818302601"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.06.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}